Cargando…

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination

This study aimed to determine the population pharmacokinetic (Pop PK) parameters of cefazolin administered prophylactically at 25 mg/kg intravenously (IV) 30 min before surgery in a canine population of 78 dogs and assess whether covariates, such as sex, age, body weight (BW), breed, health status,...

Descripción completa

Detalles Bibliográficos
Autores principales: Cagnardi, Petra, Di Cesare, Federica, Toutain, Pierre-Louis, Bousquet-Mélou, Alain, Ravasio, Giuliano, Villa, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190795/
https://www.ncbi.nlm.nih.gov/pubmed/30356800
http://dx.doi.org/10.3389/fphar.2018.01137
_version_ 1783363623662387200
author Cagnardi, Petra
Di Cesare, Federica
Toutain, Pierre-Louis
Bousquet-Mélou, Alain
Ravasio, Giuliano
Villa, Roberto
author_facet Cagnardi, Petra
Di Cesare, Federica
Toutain, Pierre-Louis
Bousquet-Mélou, Alain
Ravasio, Giuliano
Villa, Roberto
author_sort Cagnardi, Petra
collection PubMed
description This study aimed to determine the population pharmacokinetic (Pop PK) parameters of cefazolin administered prophylactically at 25 mg/kg intravenously (IV) 30 min before surgery in a canine population of 78 dogs and assess whether covariates, such as sex, age, body weight (BW), breed, health status, creatinine level, and surgery time, have an influence on cefazolin disposition. The ultimate goal was to compute PK/PD cut off values and subsequently establish a specific clinical breakpoint (CBP) for the development of an antimicrobial susceptibility test (AST) of cefazolin in dogs according to the VetCAST approach. Two to 11 blood samples were collected from each dog from 5 to 480 min after cefazolin administration. A two-compartment model was selected, and parameterization was in terms of serum clearance (CL), intercompartmental CL(s) (Q) and volume(s) of distribution (V). The percentage of cefazolin binding to serum protein was 36.2 ± 5.3%. Population primary parameter estimates V1, V2, CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg, 0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively. Cefazolin presented rapid distribution and elimination half-lives (mean ± SE) 4.17 ± 0.77 min and 57.93 ± 3.11 min, respectively. The overall between-subject variability (BSV) for estimated primary parameters ranged from 36 to 42%, and none of the seven explored covariates were able to reduce this variability by an amplitude clinically relevant. By Monte Carlo simulation, the probability of a PK/PD target attainment (here to achieve a free serum concentration exceeding the MIC for 50% of the dosing interval in 90% of dogs) was computed with a dosage of 25 mg/kg administered IV every 6 h for 4 administrations in 24 h. The computed PK/PD cut off value was 2 mg/L. In conclusion, cefazolin administered prophylactically in surgical dogs at 25 mg/kg IV every 6 h was deemed effective against pathogens with a MIC value ≤ 2 mg/L and from a PK/PD perspective, can be recommended in a wide range of canine patient populations with no necessary dose adjustment for special dog subpopulations.
format Online
Article
Text
id pubmed-6190795
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61907952018-10-23 Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination Cagnardi, Petra Di Cesare, Federica Toutain, Pierre-Louis Bousquet-Mélou, Alain Ravasio, Giuliano Villa, Roberto Front Pharmacol Pharmacology This study aimed to determine the population pharmacokinetic (Pop PK) parameters of cefazolin administered prophylactically at 25 mg/kg intravenously (IV) 30 min before surgery in a canine population of 78 dogs and assess whether covariates, such as sex, age, body weight (BW), breed, health status, creatinine level, and surgery time, have an influence on cefazolin disposition. The ultimate goal was to compute PK/PD cut off values and subsequently establish a specific clinical breakpoint (CBP) for the development of an antimicrobial susceptibility test (AST) of cefazolin in dogs according to the VetCAST approach. Two to 11 blood samples were collected from each dog from 5 to 480 min after cefazolin administration. A two-compartment model was selected, and parameterization was in terms of serum clearance (CL), intercompartmental CL(s) (Q) and volume(s) of distribution (V). The percentage of cefazolin binding to serum protein was 36.2 ± 5.3%. Population primary parameter estimates V1, V2, CL, and Q were (typical value ± SE) 0.116 ± 0.013 L/kg, 0.177 ± 0.011 L/kg, 0.0037 ± 0.0002 L/kg/min, and 0.0103 ± 0.0013 L/kg/min, respectively. Cefazolin presented rapid distribution and elimination half-lives (mean ± SE) 4.17 ± 0.77 min and 57.93 ± 3.11 min, respectively. The overall between-subject variability (BSV) for estimated primary parameters ranged from 36 to 42%, and none of the seven explored covariates were able to reduce this variability by an amplitude clinically relevant. By Monte Carlo simulation, the probability of a PK/PD target attainment (here to achieve a free serum concentration exceeding the MIC for 50% of the dosing interval in 90% of dogs) was computed with a dosage of 25 mg/kg administered IV every 6 h for 4 administrations in 24 h. The computed PK/PD cut off value was 2 mg/L. In conclusion, cefazolin administered prophylactically in surgical dogs at 25 mg/kg IV every 6 h was deemed effective against pathogens with a MIC value ≤ 2 mg/L and from a PK/PD perspective, can be recommended in a wide range of canine patient populations with no necessary dose adjustment for special dog subpopulations. Frontiers Media S.A. 2018-10-09 /pmc/articles/PMC6190795/ /pubmed/30356800 http://dx.doi.org/10.3389/fphar.2018.01137 Text en Copyright © 2018 Cagnardi, Di Cesare, Toutain, Bousquet-Mélou, Ravasio and Villa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cagnardi, Petra
Di Cesare, Federica
Toutain, Pierre-Louis
Bousquet-Mélou, Alain
Ravasio, Giuliano
Villa, Roberto
Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title_full Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title_fullStr Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title_full_unstemmed Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title_short Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination
title_sort population pharmacokinetic study of cefazolin used prophylactically in canine surgery for susceptibility testing breakpoint determination
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190795/
https://www.ncbi.nlm.nih.gov/pubmed/30356800
http://dx.doi.org/10.3389/fphar.2018.01137
work_keys_str_mv AT cagnardipetra populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination
AT dicesarefederica populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination
AT toutainpierrelouis populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination
AT bousquetmeloualain populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination
AT ravasiogiuliano populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination
AT villaroberto populationpharmacokineticstudyofcefazolinusedprophylacticallyincaninesurgeryforsusceptibilitytestingbreakpointdetermination